Metabolic syndrome (MetS) is a cluster of conditions, including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. It significantly increases the risk of heart disease, stroke, and type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD), a condition characterized by the accumulation of fat in the liver, is closely linked to MetS and obesity. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are polyunsaturated fats in certain fish and plant oils. Several studies have explored the relationship between omega-3 fatty acids and metabolic health. Omega-3 supplementation has shown promising results in improving lipid profiles, reducing blood pressure, and enhancing insulin sensitivity, crucial factors in managing MetS. Additionally, omega-3 fatty acids have been found to reduce liver fat accumulation and inflammation in individuals with NAFLD, potentially slowing the progression of the disease. The mechanisms underlying the beneficial effects of omega-3 fatty acids include their ability to modulate gene expression, inhibit inflammatory pathways, and improve lipid metabolism. In conclusion, MetS and NAFLD represent significant health challenges worldwide, with implications for cardiovascular health and metabolic function. Omega-3 fatty acids, particularly EPA and DHA, offer potential therapeutic benefits in managing these conditions. However, further research is needed to elucidate the optimal dosages, sources, and long-term effects of omega-3 supplementation in individuals with MetS and NAFLD. Nevertheless, incorporating omega-3-rich foods or supplements into the diet may promote metabolic health and reduce the risk of associated complications.